Starling Oncology, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
STLN$4.00+10.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference · Filed or Furnished Herewith | |||||
|---|---|---|---|---|---|
| Exhibit Number | Description | Form | File Number | Exhibit | Filing Date |
| 2.1 | Agreement and Plan of Merger, dated as of June 28, 2021, by and among DFP Healthcare Acquisitions Corp., Orion Merger Sub I, Inc., Orion Merger Sub II, LLC and TOI Parent, Inc. | S-4/A | 333-258152 | 2.1 | October 20, 2021 |
| 3.1 | Amended and Restated Certificate of Incorporation of The Oncology Institute, Inc. | 8-K | 001-39248 | 3.1 | November 18, 2021 |
| 3.2 | Amended and Restated Bylaws of The Oncology Institute, Inc. | 8-K | 001-39248 | 3.2 | November 18, 2021 |
| 3.3 | Certificate of Designation of Series A Common Stock Equivalent Convertible Preferred Stock | 8-K/A | 001-39248 | 3.3 | November 22, 2021 |
| 3.4 | Certificate of Correction to Certificate of Designation of Preferences, Rights and Limitations of Series A Common Stock Equivalent Convertible Preferred Stock | 8-K | 001-39248 | 3.1 | March 25, 2025 |
| 3.5 | Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series A Common Stock Equivalent Convertible Preferred Stock | 8-K | 001-39248 | 3.2 | March 25, 2025 |
| 4.1 | Warrant Agreement, dated March 10, 2020, by and between DFP and Continental Stock Transfer & Trust Company, as warrant agent | 8-K | 001-39248 | 4.1 | March 13, 2020 |
| 4.2 | Specimen Preferred Stock Certificate of The Oncology Institute, Inc. | 8-K/A | 001-39248 | 4.2 | November 22, 2021 |
| 4.3 | Form of Secured Convertible Note | 8-K | 001-39248 | 4.1 | August 10, 2022 |
| 4.4 | Form of Warrant | 8-K | 001-39248 | 4.2 | August 10, 2022 |
| 4.5 | Form of pre-funded Warrant | 8-K | 001-39248 | 4.1 | March 25, 2025 |
| 4.6 | Form of Common Warrant | 8-K | 001-39248 | 4.2 | March 25, 2025 |
| 4.7 | Form of Deerfield Common Warrant | 8-K | 001-39248 | 4.3 | March 25, 2025 |
| 10.1 | Limited Consent and Amendment No. 1 to Facility Agreement, dated as of February 26, 2025, by and among The Oncology Institute, Inc., the other loan parties party thereto, the lenders party thereto and Deerfield Partners, L.P. | 8-K | 001-39248 | 10.1 | February 26, 2025 |
| 10.2 | Securities Purchase Agreement, dated March 24, 2025, by and among The Oncology Institute, Inc. and the purchasers party thereto | 8-K | 001-39248 | 10.1 | March 25, 2025 |
| 10.3 | Exchange Agreement, dated March 24, 2025, by and among The Oncology Institute, Inc., Deerfield Private Design Fund V, L.P., Deerfield Private Design Fund IV, L.P. and Deerfield Partners, L.P. | 8-K | 001-39248 | 10.2 | March 25, 2025 |
| Incorporated by Reference · Filed or Furnished Herewith | ||||||
|---|---|---|---|---|---|---|
| Exhibit Number · Description · Form · File Number · Exhibit · Filing Date | ||||||
| 10.4 | Registration Rights Agreement, dated March 26, 2025, by and among The Oncology Institute, Inc. and the investors signatory thereto | 8-K | 001-39248 | 10.1 | March 27, 2025 | |
| 31.1* | Certification Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 of the Principal Executive Officer. | X | ||||
| 31.2* | Certification Pursuant to Rule 13a-14(a) under Securities Exchange Act of 1934 of the Principal Financial Officer. | X | ||||
| 32.1** | Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer. | X | ||||
| 32.2** | Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer | X | ||||
| 101* | Interactive Data File — the following financial statements from The Oncology Institute's Quarterly Report on Form 10-Q formatted in inline XBRL (Extensible Business Reporting Language) includes: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Convertible Preferred Stock and Changes in Stockholders’ Equity, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to the Condensed Consolidated Financial Statements (Unaudited). | X | ||||
| 101.INS | XBRL Instance Document | |||||
| 101.SCH | XBRL Taxonomy Extension Schema Document | |||||
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | |||||
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | |||||
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document | |||||
| 104 | Cover Page Interactive Data File - (formatted as Inline XBRL and contained in Exhibit 101) | |||||
| * | Filed herewith. | |||||
| ** | Furnished herewith. | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.